PepGen Inc. announced its participation in the 29th Annual Congress of the World Muscle Society, where it presented preclinical and clinical data for its Duchenne Muscular Dystrophy (DMD) and Myotonic Dystrophy Type 1 (DM1) programs. The presentations highlighted ongoing research and development efforts across its pipeline.
The company provided an update on the safety profile of PGN-EDO51 in the CONNECT1-EDO51 trial as of October 3, 2024. PGN-EDO51 demonstrated a favorable emerging safety profile in both the 5 mg/kg and ongoing 10 mg/kg cohorts, with no serious adverse events reported.
All treatment-related adverse events observed were mild and resolved, including one instance of hypomagnesemia that resolved with oral supplementation. All participants in the CONNECT1 study continued as planned, with no discontinuations, dose interruptions, or reductions.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.